<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02152956</url>
  </required_header>
  <id_info>
    <org_study_id>CP-MGD006-01</org_study_id>
    <nct_id>NCT02152956</nct_id>
  </id_info>
  <brief_title>Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MacroGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MacroGenics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study now is to assess the anti-neoplastic activity of&#xD;
      flotetuzumab in patients with PIF/ER AML, as determined by the proportion of patients who&#xD;
      achieve complete remission (CR) or complete remission with partial hematologic recovery&#xD;
      (CRh).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label, multi-dose, single-arm, multi-center, Phase 1/2 study conducted in three&#xD;
      segments: the Single Patient Dose Escalation Segment (complete), followed by the&#xD;
      Multi-Patient Dose Escalation Segment (complete) and the Maximum Tolerated Dose and Schedule&#xD;
      (MTDS) Expansion Cohort Segment (ongoing). Having characterized safety and determined the&#xD;
      maximum tolerated dose and schedule, the primary objective of this study now is to assess the&#xD;
      anti-neoplastic activity of flotetuzumab in patients with PIF/ER AML, as determined by the&#xD;
      proportion of patients who achieve CR or CRh. Starting with Cycle 2, patients who are&#xD;
      benefiting from flotetuzumab may receive up to a maximum of 8 cycles of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2014</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy based on CR/CRh rate</measure>
    <time_frame>14 months</time_frame>
    <description>Proportion of patients achieving a best response of CR (morphologic CR [mCR], cytogenetic CR [CRc], molecular CR [CRm], or CRh per Interworking Group AML response criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall complete response rate</measure>
    <time_frame>14 months</time_frame>
    <description>Rate of CR + CRh + CRi (CR with incomplete blood cell recovery [CR with incomplete neutrophil or platelet recovery]) + MLFS (morphologic leukemia-free state)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR rate</measure>
    <time_frame>14 months</time_frame>
    <description>Proportion of patients achieving a best response of CR (morphologic CR [mCR], cytogenetic CR [CRc], or molecular CR [CRm] per Interworking Group AML response criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRh rate</measure>
    <time_frame>14 months</time_frame>
    <description>Proportion of patients achieving a best response of CRh per Interworking Group AML response criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Time of initial documentation of response to the time of disease relapse or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion independence rate</measure>
    <time_frame>56 days</time_frame>
    <description>The rate of conversion from transfusion dependence to transfusion independence will be calculated. The rate of patients who are transfusion independent at baseline and remain independent during any 56-day post-baseline period will also be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Time from first dose to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HSCT rate</measure>
    <time_frame>8 months</time_frame>
    <description>Rate of successful hematopoietic stem cell transplantation (HSCT) through flotetuzumab treatment but before subsequent therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of hospitalization</measure>
    <time_frame>8 months</time_frame>
    <description>Incidence rate of hospitalization will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>8 months</time_frame>
    <description>Duration of hospitalization will be characterized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Time from the first dose of study drug until date of evidence of progression, relapse, or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>14 months</time_frame>
    <description>Time from first dose of study drug to first CR, CRh, CR with incomplete blood cell recovery (CRi), CR with incomplete neutrophil recovery (CRn), CR with incomplete platelet recover (CRp), or morphologic leukemia-free state (MLFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>Up to 180 days</time_frame>
    <description>rate of death from any cause within 30, 60, 90, or 180 days of first dose of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month survival rate</measure>
    <time_frame>6 months</time_frame>
    <description>Probability of survival at 6 months from first dose of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-year survival rate</measure>
    <time_frame>1 year</time_frame>
    <description>Probability of survival at 1 year from first dose of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion related reaction (IRR)/cytokine release syndrome (CRS) management</measure>
    <time_frame>During study drug administration (up to 8 months)</time_frame>
    <description>Determine safety and efficacy of tocilizumab in the treatment of IRR/CRS as measured by incidence of IRR/CRS</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Occurrence of dose limiting toxicity</measure>
    <time_frame>Cycle 1 of a 28 day cycle.</time_frame>
    <description>Maximum Tolerated Dose/Schedule: the MTDS is defined as the highest dose/schedule administered during any Cohort in the study at which the incidence of DLT is &lt; 33% during the first cycle of MGD006 treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>9 months</time_frame>
    <description>Cycle 1 through end of treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum concentration of flotetuzumab</measure>
    <time_frame>Cycles 1 and 2 (28-day cycles) and 28 days after the last dose</time_frame>
    <description>Measure the pharmacokinetics (PK) of flotetuzumab</description>
  </other_outcome>
  <other_outcome>
    <measure>ADA</measure>
    <time_frame>Day 1 of Cycle 1 and Day 1 of Cycle 2 (28-day cycles)</time_frame>
    <description>Occurrence of anti-drug antibody</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>AML</condition>
  <arm_group>
    <arm_group_label>Flotetuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD123 x CD3 bispecific DART® antibody</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flotetuzumab</intervention_name>
    <description>Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART® molecule.</description>
    <arm_group_label>Flotetuzumab</arm_group_label>
    <other_name>MGD006</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of primary or secondary AML [any subtype except acute&#xD;
             promyelocytic leukemia (APL)] according to World Health Organization (WHO)&#xD;
             classification&#xD;
&#xD;
          -  Patients with AML must meet one of the following criteria, a or b:&#xD;
&#xD;
             a. Primary Induction Failure (PIF) AML, defined as disease refractory to one of the&#xD;
             following, i or ii: i. An intensive induction attempt, per institution. Induction&#xD;
             attempts include high-dose and/or standard-dose cytarabine&#xD;
&#xD;
             ± an anthracyclines/anthracenedione ± an anti-metabolite, with or without growth&#xD;
             factor or targeted therapy containing regimens.&#xD;
&#xD;
        Examples include but are not limited to:&#xD;
&#xD;
          1. One cycle of high dose cytarabine (HiDAC) containing regimen&#xD;
&#xD;
          2. One cycle of liposomal cytarabine and daunorubicin&#xD;
&#xD;
          3. Two cycles of standard dose cytarabine containing regimen ii. For adults who are age&#xD;
             75 years or older, or who have comorbidities that preclude use of intensive induction&#xD;
             chemotherapy; PIF is defined as AML refractory to one of the following less intensive&#xD;
             regimens, 1 or 2:&#xD;
&#xD;
        1. ≥ 2 but ≤ 4 cycles of Bcl-2 inhibitors in combination with azacitidine, decitabine, or&#xD;
        low dose cytarabine 2. ≥ 2 but ≤ 4 cycles of gemtuzumab ozogamicin monotherapy b. Early&#xD;
        relapse (ER) AML, defined as AML in first relapse with initial CR1 duration &lt; 6 months 3.&#xD;
        Limit of 3 prior lines of therapy: up to 2 induction (induction, re-induction) or 1&#xD;
        induction plus/minus 1 consolidation attempt, followed by a maximum of 1&#xD;
        salvage/re-induction attempt.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2&#xD;
&#xD;
          -  Life expectancy of at least 4 weeks&#xD;
&#xD;
          -  Peripheral blast count &lt;/= 20,000/mm3 at the time of first dose&#xD;
&#xD;
          -  Acceptable laboratory parameters and adequate organ reserve&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allogeneic stem cell transplantation&#xD;
&#xD;
          -  Prior treatment with an anti-CD123-directed agent&#xD;
&#xD;
          -  Need for concurrent other cytoreductive chemotherapy&#xD;
&#xD;
          -  Any active untreated autoimmune disorders (with the exception of vitiligo, resolved&#xD;
             childhood atopic dermatitis, prior Grave's disease now euthyroid clinically and with&#xD;
             stable supplementation)&#xD;
&#xD;
          -  Second primary malignancy that requires active therapy. Adjuvant hormonal therapy is&#xD;
             allowed.&#xD;
&#xD;
          -  Antitumor therapy or investigational agent within 14 days or 5 half-lives of Cycle 1&#xD;
             Day 1.&#xD;
&#xD;
          -  Requirement, at the time of study entry, for concurrent steroids &gt; 10 mg/day of oral&#xD;
             prednisone or the equivalent, except steroid inhaler, otic preparations, nasal spray&#xD;
             or ophthalmic solution&#xD;
&#xD;
          -  Use of immunosuppressant medications in the 2 weeks of Cycle 1 Day 1&#xD;
&#xD;
          -  Use of granulocyte colony stimulating or granulocyte-macrophage colony stimulating&#xD;
             factor in the 2 weeks of Cycle 1 Day 1&#xD;
&#xD;
          -  Known central nervous system (CNS) leukemia&#xD;
&#xD;
          -  Active uncontrolled infection (including, but not limited to viral, bacterial, fungal,&#xD;
             or mycobacterial infection),&#xD;
&#xD;
          -  Known human immunodeficiency virus infection, unless all of the following criteria are&#xD;
             met:&#xD;
&#xD;
             i. CD4+ count ≥ 350 cells/μL, ii. undetectable viral load, and iii. receiving highly&#xD;
             active antiretroviral therapy.&#xD;
&#xD;
          -  Known, active, history of or current acute or chronic hepatitis B or C virus (HBV)&#xD;
             infection (as evidenced by detectable HBV surface antigen and HBV DNA ≥ 500 IU/mL),&#xD;
&#xD;
          -  History of hepatitis C virus (HCV) infection, unless the infection has been treated&#xD;
             and cured,&#xD;
&#xD;
          -  Active SARS-CoV-2 infection. While SARS-CoV-2 testing is not mandatory for study&#xD;
             entry, testing for ongoing infection should follow local clinical practice&#xD;
             guidelines/standards. Participants with a positive test result for ongoing SARS-CoV-2&#xD;
             infection, known asymptomatic infection, or suspected infection are excluded unless or&#xD;
             until asymptomatic and with subsequent negative SARS-CoV-2 laboratory test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John DiPersio, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen L. Eck, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>MacroGenics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Vey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute Paoli-Calmettes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathy Tran</last_name>
    <email>trank@Macrogenics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dianne Yu</last_name>
      <phone>626-256-4672</phone>
      <phone_ext>83524</phone_ext>
      <email>diyu@coh.org</email>
    </contact>
    <investigator>
      <last_name>Ibrahim Aldoss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marisa Wiegand</last_name>
      <phone>858-822-6396</phone>
      <email>mwiegand@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emma Bishop</last_name>
      <phone>858-822-1960</phone>
      <email>e2Bishop@ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Wieduwilt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Nattinger</last_name>
      <phone>415-514-4805</phone>
      <email>Caroline.Nattinger@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Sayre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Gleason</last_name>
      <phone>404-778-4334</phone>
      <email>Shannon.gleason@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Martha Arellano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Kflu</last_name>
      <phone>410-328-9416</phone>
      <email>veronica.kflu@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Ashkan Emadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxana Taralunga</last_name>
      <phone>734-232-0773</phone>
      <email>roxanat@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Kristen Petit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayan Gasanli</last_name>
      <phone>314-747-2449</phone>
      <email>agasanli@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Geoffrey Uy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John DiPersio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison McKinney</last_name>
      <phone>919-966-4432</phone>
      <email>allison_mckinney@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Mathew C. Foster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Stowe, BSN, RN</last_name>
      <phone>919-681-4769</phone>
      <email>rachel.stowe@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Harry Erba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaylee Root</last_name>
      <phone>216-444-3576</phone>
      <email>ROOTK2@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Eric Wiedenfeld</last_name>
      <phone>216-445-0003</phone>
      <email>wiedene@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Anjali Advani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neysa Dagostino, RN, OCN</last_name>
      <phone>503-215-2608</phone>
      <email>neysa.dagostino@providence.org</email>
    </contact>
    <investigator>
      <last_name>John Godwin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dino Francescutti</last_name>
      <phone>615-875-9980</phone>
      <email>dino.francescutti@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Michael T Byrne, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa J. McFarland</last_name>
      <phone>713-745-1216</phone>
      <email>MJMacFarland@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Farhad Ravandi-Kashani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cherise Athay</last_name>
      <email>cathay@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Ronald Walter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katelyn Gauger</last_name>
      <phone>414-805-4587</phone>
      <email>kgauger@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Laura Michaelis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Veuillen</last_name>
      <email>veuillenc@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Norbert Vey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lea Robert</last_name>
      <email>lea.robert@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Patrice Chevallier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse-Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elodi Judic</last_name>
      <phone>+33 5 31 15 58 74</phone>
      <email>judic.elodie@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Christian Recher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours - Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiba El Sayadi Bizri</last_name>
      <email>H.BIZRIELSAYADI@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel Gyan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margrit Stodder</last_name>
      <phone>+49 30 450553862</phone>
      <email>Margrit.stodder@charite.de</email>
    </contact>
    <investigator>
      <last_name>Lars Bullinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Max Langner</last_name>
      <email>max.langner@uniklinikum-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Martin Wermke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Petra Kuhne</last_name>
      <phone>+040 741054353</phone>
      <email>p.kuehne@uke.de</email>
    </contact>
    <investigator>
      <last_name>Walter Fiedler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karolin Hubert</last_name>
      <phone>+ 49 341 97-20363</phone>
      <email>karolin.hubert@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Sebastian Schwind, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Britta Vornwald</last_name>
      <phone>+49 6131 17 5160</phone>
      <email>britta.vornwald@unimedizin-mainz.de</email>
    </contact>
    <investigator>
      <last_name>Marcus Radsak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>III. Med. Klinik-Klinikum rechts der Isar-Technische Universität München</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Ernst</last_name>
      <phone>+49 89 41405145</phone>
      <email>christine.ernst@mri.tum.de</email>
    </contact>
    <investigator>
      <last_name>Katharina Gotze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und II, Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzbur</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johana Reif</last_name>
      <email>Reif_J@ukw.de</email>
    </contact>
    <investigator>
      <last_name>Max Topp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cinzia Bonajuto</last_name>
      <email>cinzia.bonajuto@studio.unibo.it</email>
    </contact>
    <investigator>
      <last_name>Piere Luigi Zinzani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)</name>
      <address>
        <city>Meldola</city>
        <zip>74014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederica Frabetti</last_name>
      <phone>390543739292</phone>
      <email>federica.frabetti@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Lucchesi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Vita-Salute San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefania Trinca</last_name>
      <email>trinca.stefania@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Fabio Ciceri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa di Ematologia Ospedale Santa Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <zip>48123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Fabbri</last_name>
      <phone>0039 054 428 5103</phone>
      <email>francesca.fabbri@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Lanza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erna Helmantel</last_name>
      <email>e.helmantel@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Gerwin Huls, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Longergan</last_name>
      <email>s.lonergan@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Bob Lowenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's Health Partners</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lajos Floro</last_name>
      <phone>44 20 3299 5777</phone>
      <email>lajos.floro@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Victoria Potter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ryan Roberts</last_name>
      <phone>+44 161 446 3000</phone>
      <email>Ryanjames.Roberts@christie.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Michael Dennis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2014</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>leukemia</keyword>
  <keyword>myelogenous</keyword>
  <keyword>myeloid</keyword>
  <keyword>refractory</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

